|
Nov 28
|
Loss-Making Outlook Therapeutics, Inc. (NASDAQ:OTLK) Expected To Breakeven In The Medium-Term
|
|
Nov 27
|
Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010
|
|
Nov 2
|
Outlook Therapeutics® Provides Update on Type A Meetings with FDA
|
|
Nov 1
|
Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) Conference
|
|
Apr 27
|
Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference
|